KRAS Wild-Type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential

Clin Cancer Res. 2023 Nov 14;29(22):4527-4529. doi: 10.1158/1078-0432.CCR-23-2221.

Abstract

In a landscape dominated by pivotal KRAS mutations, there has been limited exploration of KRAS wild-type pancreatic cancer. A recent study highlights other mitogen-activated kinase pathway alterations as alternative drivers in these tumors, which holds the key to unlocking a realm of targeted therapies for patients with this understudied cancer subtype. See related article by Singh et al., p. 4627.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Genomics
  • Humans
  • Mutation
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / genetics
  • Proto-Oncogene Proteins p21(ras)* / genetics
  • Proto-Oncogene Proteins p21(ras)* / metabolism

Substances

  • Proto-Oncogene Proteins p21(ras)
  • KRAS protein, human